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Patients with portal hypertension of varying etiology may
develop pulmonary artery hypertension. In the present
autopsy study, pulmonary and hepatic tissue was studied
in 12 patients in whom pulmonary and portal hyperten-
sion coexisted. Plexogenic pulmonary arteriopathy was
present in 10 patients, 7 of whom had coexistent throm-
boembolic lesions. One patient had isolated medial hy-
pertrophy, which may be an early stage in the plexogenic
category, whereas isolated thromboembolic pulmonary
vascular disease was observed in one subject. Hepatic
disease was consistent with alcoholic cirrhosis in seven
The development of pulmonary artery hypertension in in-
dividuals with portal hypertension is a rare but recognized
syndrome (1-13). Among affected individuals, the pul-
monary component may represent the major source of mor-
bidity and mortality. The morphology of the obstructive
pulmonary vascular disease has been described as either
thromboembolic (I) or plexogenic (8,10,12).
Thromboembolic pulmonary hypertension in conjunction
with portal hypertension is characterized either by the pres-
ence of thrombotic material or by reactions to such material,
involving small muscular arteries or arterioles, or both. It
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patients, cryptogenic cirrhosis in four and extrahepatic
portal hypertension without cirrhosis in one. Throm-
bocytopenia was present in all 10 patients whose platelet
count was determined.
This study suggests that pulmonary hypertension as-
sociated with portal hypertension commonly has a plex-
ogenic appearance on histologic examination. However,
thrombosis (whether embolic or in situ) may also con-
tribute to vascular obstruction.
(J Am Coli Cardiol1987;10:1233-8)
is recognized that organization of thrombotic material may
be represented by a constellation of forms, including fibrous
mural pads, occlusive nonvascular or vascular fibrous tissue
and fibrous septa crossing the vascular lumens.
In contrast, plexogenic pulmonary hypertension may ap-
pear in several morphologic stages. The ultimate specific
feature of this type of pulmonary hypertension is the pres-
ence of the plexiform lesion. Nevertheless, earlier stages
are generally present, including medial hypertrophy and
concentric intimal proliferation, as well as fibrinous degen-
eration and arteritis. The medial hypertrophy may reflect an
element of pulmonary artery vasoconstriction in the origin
of plexogenic pulmonary hypertension (14).
From the tiles of the Cardiovascular Registry of United
Hospital, 51. Pau\' the Department of Pathology of the Vet-
erans Administration Medical Center, Minneapolis and the
Mayo Clinic, Rochester, Minnesota, autopsy material was
obtained from 12 patients in each of whom pulmonary artery
hypertension occurred in conjunction with portal hyperten-
sion. The syndrome, although rare, may provide insight into
the etiology of primary pulmonary hypertension. which af-
fects a larger group of patients. In this report, clinical fea-
tures and pathologic findings are reviewed. Data are reported
for individual cases and mean values ± standard error are
reported.
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Patients. Twelve patients were identified who had evi-
dence for clinically significant pulmonary hypertension and
portal hypertension. The clinical characteristics are sum-
marized in Table I. There were seven men (average age 51
± 6 years) and five women (average age 47 ± 4 years).
In all patients whose clinical data were available to us, the
physical examination disclosed signs of pulmonary hyper-
tension.
The electrocardiogram demonstrated signs of right ven-
tricular hypertrophy in each ofthe 12 patients. The thoracic
roentgenogram was abnormal in all and demonstrated en-
larged pulmonary arteries in five patients, cardiomegaly in
four and both enlarged pulmonary arteries and cardiomegaly
in three. A radionuclide pulmonary perfusion scan, per-
formed in four patients, did not demonstrate any segmental
areas of hypoperfusion.
Cardiac catheterization and angiography. In 9 of the
12 patients, right-sided cardiac catheterization had been per-
formed and demonstrated severe pulmonary artery hyper-
tension (mean pulmonary artery systolic and diastolic pres-
sures 92 ± 8 and 41 ± 3 mm Hg, respectively). Information
regarding the pulmonary artery wedge or left ventricular
end-diastolic pressures was available in six cases and find-
ings were normal in each. In no case was an intracardiac
shunt demonstrated. The cardiac index was reported in five
and averaged 2.1 ± 0.30 liters/min per rrr'. Pulmonary an-
giography was performed in four cases, and no intraluminal
filling defects were demonstrated. However, in two in-
stances there was distal "pruning" of the small pulmonary
arteries.
Etiology. On the basis of clinical and pathologic infor-
mation, the cause of the portal hypertension was considered
Table 1. Clinical Features of 12 Patients
to be secondary to alcoholic cirrhosis in seven patients,
cryptogenic cirrhosis in four and extrahepatic portal hyper-
tension without cirrhosis in one (Case 3). The latter patient
was a 25 year old man with a history of neonatal omphalitis
that resulted in sclerosis of the hepatic veins and portal
hypertension with preservation of hepatic architecture. Seven
patients experienced episodic gastrointestinal hemorrhage.
In two patients, a portosystemic shunt had been created
surgically. A LeVeen shunt was placed to drain ascitic fluid
into the superior vena cava in one patient. Retrospective
reviews demonstrated that in 7 of 12 subjects whose symp-
toms related primarily to pulmonary hypertension, the av-
erage duration of symptoms before death was 43 ± 14
months (range 2 to 96).
Thrombocytopenia. Each of the eight patients in whom
platelet counts had been obtained exhibited mild thrombo-
cytopenia (mean platelet count 76,400 ± 8,300). In two
other patients, a peripheral blood smear was reported to
show decreased platelets. This thrombocytopenia is in com-
parison with a mean platelet count of 158,000 ± 40,000
in nine other patients (mean age 61 years) who had portal
hypertension and esophageal varices. These patients were
found at autopsy to have cirrhosis, but no significant pul-
monary vascular disease.
Pathologic Features
The gross features of the organs had been described in
the reports of the autopsies. Slides for histologic exami-
nation were directly reviewed by us in each case. Pulmonary
tissues for histologic study had been stained with hematox-
ylin-eosin and elastic-van Gieson. The pertinent pathologic
features for each case are summarized in Table 2.
Gross features. The heart was enlarged in each case.
The average recorded heart weight (n = II) was 535 ±
Case Age (yr) History of GI PA Pressure Platelet
No. &Sex Alcoholic Bleeding (mm Hg) Count/rnm '
I 68M + + 115/30 50,000
2 56M 90/37 51,700
3 25M + 56/36 NA
4 74F NA Redc
5 45F + + 110/40 69,000
6 42M + 80/NA NA
7 58M + + NA 70.000
8 40M + + 110/51 102,000
9 38F + + 65/42 60,000
10 51F 80/NA Redc
II 28F 120/50 106,000







F = female; GI = gastrointestinal; M = male; NA = not available; PA = pulmonary artery; Redc =
reduced platelets on peripheral smear; + = yes; - = no.
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Table 2. Pathologic Features in 12 Cases
Case Heart Liver Hepatic Pulmonary Vascular
No. Weight (gl Weight (gl Disease Disease
680 1,420 AC Medial hypertrophy
2 NA NA Crypto Plex
3 740 1.080 HPC Plex
4 620 750 Crypto PIex
5 450 1.660 AC Plex and throm
6 630 1.800 AC Plex and throrn
7 650 850 AC Plex and throrn
8 520 1.200 AC Plex and throm
9 465 1.250 AC + hepatoma Plex and throm
10 380 1.080 Crypto Plex and throm
11 365 1.095 Crypto Plex and throrn
12 400 1.770 AC + hepatoma Throm
AC alcoholic cirrhosis; Crypto = cryptogenic cirrhosis: HPC = hepatoportal sclerosis; NA = not
available; Plex = plexogenic pulmonary arteriopathy: Throm = thromboembolic pulmonary vascular disease.
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40 g (range 380 to 740 ). Isolated right ventricular hyper-
troph y was present in II cases, and biventri cular hypertro-
phy was present in one case . The atrial and ventricular septa
were intact , and there were no gross communications be-
tween the great vessels . The card iac valves were normal.
In each case, there was evidence of portal hypertension
with an extensively developed portal-systemic collateral sys-
tem . The average weight of the liver was 1,280 ± 106 g
(range 750 to 1,800). On gross examination , there was
obvious cirrhosis in II of the 12 cases . In one case (Case
3), the liver was fibrotic with no ev idence of regenerative
nodule s , but with fibrosis and obliteration of the portal veins .
In two cases with cirrhosis (Cases 9 and 12), solitary he-
patocellular carcinoma was also present. Portosystemic shunts
had been surgically created in two patients (Cases 3 and 7) .
In Case 7, there was no evidence of thrombosis, and the
shunt was widely patent. In Case 3, the patient had had two
shunt procedures . A splenorenal shunt had been constructed
when the patient was 9 year s old. Thi s later thrombosed ,
after which a portocaval shunt was constructed . At autopsy ,
the splenorenal shunt was found to be occ luded by organi zed
thrombu s . The portocaval shunt was patent without ev idence
of thrombosis. In one case (Case 6), a LeVeen shunt was
in place and there was evidence of thrombosis in and around
the shunt.
Histologic features. Liver. Histologic examination of
the liver demonstrated chan ges con sistent with the clinical
history of alcoholic liver disease in seve n cases . In four
cases , each with no history of alcohol abuse, the hepatic
disease was classified as cryptoge nic cirrhos is . Among these
were two women (Cases 10 and II ) with coexisten t con-
nective tissue disorders (rheumatoid arthritis and Sjogren 's
syndrome) . Hepatoportal sclerosis was present in the one
case without cirrhosis (Case 3) .
Lungs. Histologic examination of the lungs showed that
each case exhibited one of four patterns of pulmonary artery
disease as follow s: I ) medial hypertrophy of muscular ar-
ter ies (Fig. lA); 2) thromb oembolism (Fig . IB ); 3) plexi -
form lesions (Fig . 2); and 4) coex istence of plexiform and
thromboembolic lesions. Medial hypertrophy was the only
vascular change observed in one case (Case I) , although it
was present to some degree in each of the other cases.
Thromboembolism was the predominant feature in one case
(Case 12). and plexogenic pulmonary arteriopathy alone was
present in three cases (Cases 2 to 4) . Seven cases (Cases 5
to II ) exhibited both plexiform and thrombotic lesion s.
Discussion
In this study, histologic materi al from 12 patients with
portal hypertension and associated pulmonary artery hy-
pertension was examined . Although this syndrome is most
commonly reported in patients with hepati c cirrhosis, it
appea rs that portal hypert ension and not cirrhosis in itself
is the necessary prerequ isite . Other investigators (5 ,7, 9)
have also described patients with pulm onary hypertension
and portal hypertension without cirrhosis.
Pulmonary Vascular Disease
Plexogenic arteriopathy: pulmonary vasoconstric-
tion. Among the patterns of pulmonary vascular disease
observed, two were distinct morph ologic types-plexogenic
arteriopathy (including isolated medial hypertrophy) and
thromb oemb olic disease . Th e full picture of plexogenic ar-
teriopathy includes plexiform lesions in association with
medial hypertrophy and nonspecific intimal fibrous thick-
ening. It is generally considered that pulmonary vasocon-
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Figure 1. A, Case I. Medium-sized muscular artery of the lung
shows medial hypertrophy. Elastic tissue stain; magnification x 63.
B, Case 12. Large muscular artery shows mild medial thickening.
The lumen isrepresented bythree spaces. The picture isconsidered
torepresent recanalization ofanorganized thrombus. Elastic tissue
stain; magnification x 100.
striction is one factor in the etiology of the plexogenic type
of clinical primary pulmonary hypertension (15). Thus, when
pulmonary hypertension is associated with portal hyperten-
sion, pulmonary vasoconstriction may also be important.
Although this syndrome is rare, it may represent an "ac-
cident of nature" that can provide clues to the etiology of
the more common types of primary pulmonary hyperten-
sion. Among patients with portal hypertension and a por-
tosystemic shunt, any vasoconstrictor that is produced in
the portal circulation and normally metabolized by the liver
might escape metabolism and lead to pulmonary vasocon-
striction. The specific agent or agents responsible for pul-
monary vasoconstriction were not investigated as part of
this study. However, one could speculate that potential sub-
stances would include serotonin, neuropeptide Y, throm-
boxanes or a deficiency of vasodilatory prostaglandins
(16-19). In addition, localized platelet aggregation within
Figure 2. Case 4. Plexiform lesions. In the center is the parent
muscular artery showing medial hypertrophy. To the right are two
branches in which the lumens contain the cellular proliferation
characteristic of plexiform lesions. Hematoxylin-eosin stain; orig-
inal magnification x 150, reduced by 10%.
pulmonary vessels has been demonstrated (16) to result in
pulmonary vasoconstriction, most likely mediated by the
release of serotonin. Similarly, an agent such as endotoxin,
which can cause vascular damage and pulmonary hyperten-
sion (20), may not be taken up by the liver (21). It is less
likely, but theoretically possible, that a substance from the
splanchnic circulation is normally transformed in the liver
to a vasodilator metabolite and that this does not occur in
the presence of portal hypertension.
The cause of the thrombocytopenia in these patients is
not clear. It may be that portal hypertension leads to spleno-
megaly with concomitant sequestration and destruction of
platelets. However, nine other patients with portal hyper-
tension severe enough to cause esophageal varices had sig-
nificantly higher platelet counts. If the thrombocytopenia is
in part related to the pulmonary hypertension, it is unknown
whether this represents a primary or secondary process.
It has been postulated that in some patients with plexo-
genic pulmonary hypertension. thrombocytopenia may oc-
cur as a secondaryphenomenon because of damage to plate-
lets passing through the plexiform lesions (22). However.
platelet survival has also been shown to be decreased in
JACC Vol. 10. No.6
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patients with hypoxemia and pulmonary hypertension in
whom plexiform lesions would not be anticipated (23).
Coexistent thrombosis. In seven of the cases with plex-
ogenic pulmonary arteriopathy, coexistent microscopic
thrombosis was observed. Thrombi were present in medium
and small vessels and were in various stages of organization.
Prior studies by Fuster et al. (24) have similarly documented
that it is "not infrequent" for arterial thrombi to coexist
with plexogenic pulmonary arteriopathy. The current data
are insufficient to explain the cause of this thrombosis; how-
ever, one may speculate that the thrombosis is secondary
to one or more of several possible mechanisms, including
stasis or local endothelial injury with secondary thrombosis.
Studies (25) have documented that primary pulmonary hy-
pertension is uniquely characterized by an increase in the
ratio of ristocetin cofactor activity to von Willebrand factor
antigen, suggesting significant endothelial cell injury. Such
injury could predispose to secondary thrombosis. A less
likely possibility is that the phenomenon of coexistent
thrombosis and plexogenic arteriopathy represents a more
generalized hypercoagulable state.
Platelet-endothelium interaction. The possibility re-
mains that platelet-endothelium interaction plays an etio-
logic role in some forms of pulmonary hypertension. Plate-
lets contain a substance that stimulates the growth of monkey
(26,27) and human (28) arterial smooth muscle cells. The
platelet-derived growth factor is located in the same granules
as beta-thromboglobulin, and both are released together from
the platelet (28). Elevated plasma beta-thromboglobulin lev-
els have been measured in patients with chronic obstructive
pulmonary disease and cor pulmonale, suggesting increased
platelet activation (29). Administration of dipyridamole re-
turned the values to normal levels. Similarly, antiplatelet
therapy prevented the increase in platelet consumption and
pulmonary vascular resistance caused by the creation of a
systemic to pulmonary artery shunt in the dog (30). It may
be that, in some individuals with portal hypertension, pul-
monary vascular endothelial injury and platelet activation
occur, in time giving rise to the histologic appearance of
medial hypertrophy and intimal fibrosis.
Conclusions. The current study, retrospective and pri-
marily descriptive in nature, identifies the clinical and mor-
phologic features observed in subjects with coexistent pul-
monary and portal hypertension and suggests that pulmonary
vasoconstriction and thrombosis are common in this entity.
Although the data provided do not delineate the primary
mechanism responsible for this phenomenon, they do detail
the morphologic findings and thereby enhance the founda-
tion for future studies of this mechanism.
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